St. Jude Medical Inc. (NYSE:STJ) won CE Mark approval for its MRI-safe Accent pacemaker and Tendril lead, gaining on the lead its Twin Cities competitor Medtronic (NYSE:MDT) established with its Revo MRI-safe system.
Boston Scientific
Boston Scientific to cut Minnesota workforce by up to 10 percent
It turns out the rumors were true: Minnesota-based employees of Boston Scientific Corp. (NYSE:BSX) began receiving pink slips this week.
Reports surfaced last month that the Natick, Mass.-based medical device giant was planning to lay off workers from its cardiology, rhythm and vascular business in the Twin Cities.
Boston Scientific wins a round in stent war with J&J’s Cordis Corp.
The long-running battle between Boston Scientific Corp. (NYSE:BSX) and Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. over coronary stent patents went another round this week when a federal judge ruled that Cordis infringes a BSX patent.
Judge Susan Robinson of the U.S. District Court for Delaware granted the Natick, Mass.-based catheter pioneer’s move for summary judgment of infringement and denied a Cordis motion to delay the jury trial phase of the case, slated to begin May 5.
U.S. judge OKs Angiotech bankruptcy plan
A federal judge in Delaware rubber-stamped Angiotech Pharmaceutical’s (OTC:ANPI) bankruptcy plan, writing that it’s the best deal possible and serves the interest of "international comity."
The settlement, already approved by the Supreme Court of British Columbia, is aimed at eliminating $250 million in debt under Canada’s Companies’ Creditors Arrangement Act. It will largely wipe out the company’s existing shareholders, apart from a group connected with its 2006 acquisition of Quill Medical Inc.
ACC 2011 Roundup: Acute interventions almost always appropriate
A review of half a million cases from the National Cardiovascular Data Registry finds that almost all acute percutaneous coronary interventions meet "acceptable" guidelines, but showed that only half of elective PCIs toed the line.
Bankrupt Angiotech’s creditors OK repayment plan
Angiotech Pharmaceutical Inc. (OTC:ANPI) said it reached a settlement with its creditors to accept pennies on the dollar for their stakes in the bankrupt firm.
Neuros Medical touts pain-blocking device study | Research roundup
Neurotechnology startup Neuros Medical Inc. reported encouraging results from the first in-human study of its device that blocks pain for amputees.
The Willoughby, Ohio-based company said that four of five patients in the study reported that its device reduced their pain to “zero,” according to a statement from the company.
ACC 2011: Has Wall Street given up on stents?
ACC 2011: Positive Promus Element results don’t help Boston Scientific
Boston Scientific Corp. (NYSE:BSX) may have set the bar higher with its new Promus Element stent, at least according to one physician at the American College of Cardiology’s annual meeting, but Wall Street remains unmoved by the success.
Despite positive two-hear results from a five-year study of its next-generation Promus Element stent, the Natick, Mass.-based medical device maker’s stock slipped 1.2 percent yesterday and opened even lower today, at around $7.18.
ACC 2011: Drug-eluting stents can help in bypass surgeries
Drug-eluting stents can help patients who underwent open heart bypass surgery, according to new data, meaning they need fewer revascularization procedures after their surgeries.
Bankrupt Angiotech extends deadlines for creditors
Angiotech Pharmaceutical Inc. (OTC:ANPI) is giving its creditors a few more days to mull over a settlement that would pay them pennies on the dollar for their stakes in the bankrupt firm.